All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
The standard care for patients with early-stage unfavorable classic Hodgkin lymphoma (cHL) is treatment with four cycles of chemotherapy consolidated with 30-Gy involved-site radiotherapy (IS-RT). The chemotherapy doxorubicin, bleomycin, vinblastine, and dacarbazine regimen (ABVD) has good tolerability but insufficient long-term progression-free survival (PFS), while more intensive regimens like two cycles of dose-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone (eBEACOPP) improve 5-year PFS but are associated with adverse toxicity. Therefore, treatments with improved safety and sustained efficacy are needed.
Nivolumab, an antibody against the cell death protein 1 (PD-1), approved for relapsed cHL, has a favorable safety profile and induces high response rates. Paul J. Bröckelmann and colleagues conducted the open-label, multicenter, randomized, phase II NIVAHL study investigating nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) followed by consolidation with 30-Gy IS-RT, as first-line treatment for early-stage unfavorable cHL. The study compared the efficacy of both concomitant and sequential N-AVD dosing to establish the optimal sequence. The results of the study were published in JAMA Oncology.1
The study recruited patients aged 18–60 years with newly diagnosed, stage I-II cHL, with ≥ 1 of the following risk factors: large mediastinal mass, extranodal disease, elevated erythrocyte sedimentation rate, or three or more involved nodal areas. Patients with stage IIB who had large mediastinal mass and/or extranodal disease were excluded from the study.
Patients were stratified according to age (< 45 years vs ≥ 45 years) and gender and were randomized 1:1 to the parallel groups
After systemic treatment, both groups received consolidating 30-Gy IS-RT. Mandatory dexamethasone-based prophylaxis was administered from December 2017 onwards.
Positron emission tomography (PET)- and computed tomography (CT)-based response assessments were conducted after the four doses of nivolumab and after the end of systemic treatment. An additional CT-based restaging was performed 4–6 weeks after completion of IS-RT. In PET-positive patients, subsequent restaging was carried out 3 months after the end of IS-RT.
The primary endpoint was complete remission (CR) rate at the end of the study. Secondary points included treatment-related morbidity, PFS, overall survival (OS), early response to systemic therapy, and Grade 3–4 treatment-related adverse events.
Table 1. Selected baseline patient and disease characteristics
cHL, classic Hodgkin lymphoma; ECOG, Eastern Cooperative Oncology Group; GSHG, German Hodgkin Study Group; N-AVD, nivolumab, doxorubicin, vinblastine, dacarbazine *Out of 54 patients |
|||
Characteristics |
Concomitant N-AVD (n = 55) |
Sequential N-AVD (n = 54) |
|
Median age (range), years |
26 (18–57) |
27 (18–60) |
|
Female gender, % |
58 |
61 |
|
ECOG performance status, % 0 1 |
76 24 |
76 24 |
|
GHSG risk factors, % Large mediastinal mass Extranodal involvement Involvement of ≥ 3 nodal areas Elevated erythrocyte sedimentation rate |
13 15 71 45 |
28 11 67 50 |
|
Other potential risk factors, % Bulky disease (≥ 5cm in diameter) Vitamin D deficient (< 12 μg/L) |
58 12 |
74 18 |
|
Histological subtype, % Nodular sclerosis Mixed cellularity Lymphocyte rich cHL without subtyping |
61* 11* 4* 24* |
67 13 2* 19* |
|
Table 2. Responses during and after N-AVD therapy
CI, confidence interval, CR, complete remission, N-AVD, nivolumab, doxorubicin, vinblastine, dacarbazine, ORR, overall response rate; OS, overall survival; PFS, progression-free survival *assessed in 51 patients in the concomitant treatment group and 50 patients in the sequential treatment group |
||
Response |
Concomitant N-AVD (n = 54) |
Sequential N-AVD (n = 51) |
First restaging (after nivolumab), % ORR CR |
100 87 |
96 51 |
End of systemic therapy, % ORR CR |
100 83 |
98 84 |
End of study treatment*, % (95% CI) ORR CR |
100 90 (79–97) |
98 94 (84–99) |
12-month PFS, % (95% CI) |
100 |
98 (95–100) |
12-month OS, % |
100 |
100 |
Table 3. Morbidity and selected AEs reported in patients on N-AVD therapy
The study is the first to evaluate N-AVD as a first-line treatment for patients with high-risk cHL. The results demonstrate high efficacy and manageable toxicity profiles with either concomitant or sequenced N-AVD regimen. Response rates and early PFS were higher than previously reported in the relapse setting, suggesting that the regimen could be used in early clinical settings. Interestingly, even four doses of nivolumab monotherapy resulted in a high interim CR rate. However, a longer follow-up is required to evaluate the durability of responses and potential late-emerging treatment-related AEs.
According to the authors, this treatment could potentially offer a particular benefit to older patients with comorbidities. Something that further studies should explore.
Brockelmann PJ, Goergen H, Keller U, et al. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol. 2020. DOI: 10.1001/jamaoncol.2020.0750
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox